Navigation Links
New clues on tissue scarring in scleroderma
Date:4/18/2014

A discovery by Northwestern Medicine scientists could lead to potential new treatments for breaking the cycle of tissue scarring in people with scleroderma.

Fibrosis, or scarring, is a hallmark of the disease, and progressive tightening of the skin and lungs can lead to serious organ damage and, in some cases, death.

The concept for new therapeutic options centers on findings made by Swati Bhattacharyya, PhD, research assistant professor in Medicine-Rheumatology, who identified the role that a specific protein plays in promoting fibrosis.

"Our results show how a damage-associated protein called fibronectin (FnEDA) might trigger immune responses that convert normal tissue repair into chronic fibrosis in people with scleroderma," Bhattacharyya said. "We also found that FnEDA, which is undetectable in healthy adults, was markedly increased in the skin biopsies of patients with scleroderma."

The study was published April 16 in Science Translational Medicine.

Scleroderma remains a disease with high mortality and no effective treatment. The factors responsible for fibrosis in scleroderma are largely unknown. Working with John Varga, MD, John and Nancy Hughes Distinguished Professor of Rheumatology and director of the Northwestern Scleroderma Program, Bhattacharyya and colleagues previously showed that innate immunity is persistently activated in scleroderma patients.

To investigate the connection between immunity and fibrosis in scleroderma, the scientists looked at skin biopsies of scleroderma patients to identify factors responsible for persistent scarring. They discovered that FnEDA was highly elevated.

To test the theory that FnEDA was needed for the scarring to occur, Bhattacharyya used a genetically engineered mouse lacking the protein and discovered these mice did not develop skin fibrosis.

On a cellular level, FnEDA triggered an immune response in skin cells, leading to fibrosis. Moreover a small molecule which specifically blocks the cellular immune response triggered by FnEDA was able to prevent skin fibrosis in mice.

While the current study focused on scleroderma, the mechanisms uncovered might also underlie more common forms of fibrosis, such as pulmonary fibrosis and liver cirrhosis.

"This pioneering study using state of the art experimental approaches is the first to identify an innate immune pathway for scleroderma fibrosis," Dr. Varga said. "We expect that the results will shift our thinking about the disease, and hopefully open new avenues for its treatment."

"We have raised the possibility for developing novel therapeutic approaches," Bhattacharyya said. "We are also developing novel small molecules to selectively block the receptor for FnEDA as a potential anti-fibrotic therapy in humans."


'/>"/>

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. New clues found to preventing lung transplant rejection
2. Data on todays youth reveal childhood clues for later risk of STDs
3. Fruit fly microRNA research at Rutgers-Camden offers clues to aging process
4. New clues may link hereditary cancer genes to increased risk of cancer from alcohol
5. Stem cells offer clues to reversing receding hairlines
6. Clues to cocaines toxicity could lead to better tests for its detection in biofluids
7. Thomas Jefferson University Kimmel Cancer Center: Researchers Find New Clues to Treat Rare and Aggressive Inflammatory Breast Cancer
8. Scientists find potential new clues for identifying breast cancer risk
9. Alligator Study Gives Clues to Regrowing Lost Teeth
10. Scientists Discover More Genetic Clues to Testicular Cancer
11. Dog DNA May Yield Clues to Human Eczema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, ... be participating in Rare Disease Day events, hosted by the Rare Disease Legislative ... Report, a website, weekly e-newsletter and quarterly publication, will be conducting interviews with ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... provider for the National Institute for Health and Care Excellence (NICE) ... in the National Health Service (NHS) to search, order and purchase medical and ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
(Date:2/23/2017)... ... ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti announced the ... campaign . Individuals are now able to contribute to the local initiative, which provides ... participating patient or through an Indiegogo donation. The entirety of proceeds will go toward ...
(Date:2/22/2017)... York (PRWEB) , ... February 22, 2017 , ... ... entrance and lobby of a new healthcare contact center in Georgia, PENETRON Specialty ... One of the nation’s largest healthcare systems recently invested $51 million to purchase ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Calif. , Feb. 23, 2017 ... leading the discovery and development of innovative medicines targeting ... full year 2016 financial results on Thursday, March 2, ... host a conference call and webcast on March 2, ... quarter and full year 2016 financial results and provide ...
(Date:2/23/2017)... 23, 2017 The fast-growing cannabis market ... United States . According to the 2017 Legal Marijuana ... expected to create 283,422 jobs by 2020, with an implied ... next four years. The accelerating pace of cannabis legalization is ... legal cannabis market, which will further create more business ventures ...
(Date:2/23/2017)... South Korea , Feb. 23, 2017 LG Innotek ... UV-C LED for sterilization applications. As its sterilization performance is 1.5 ... produces the short wavelength ultraviolet rays in the range of 200 -- ... the proliferation of bacteria by destroying their DNA. LG Innotek,s product ... ...
Breaking Medicine Technology: